# EDGAR Filing Document

**Accession Number:** 0001907223
**File Stem:** 0001213900-25-109920
**Filing Date:** 2025-11
**Character Count:** 117052
**Document Hash:** c590239028452282eb4e45c576225e58
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-109920.hdr.sgml**: 20251113

**ACCESSION NUMBER**: 0001213900-25-109920

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 62

**CONFORMED PERIOD OF REPORT**: 20250930

**FILED AS OF DATE**: 20251113

**DATE AS OF CHANGE**: 20251113

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Klotho Neurosciences, Inc.
- **CENTRAL INDEX KEY:** 0001907223
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 862727441
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41340
- **FILM NUMBER:** 251477801

**BUSINESS ADDRESS:**
- **STREET 1:** 13576 WALNUT STREET, SUITE A
- **CITY:** OMAHA
- **STATE:** NE
- **ZIP:** 68144
- **BUSINESS PHONE:** (833) 931-6330

**MAIL ADDRESS:**
- **STREET 1:** 13576 WALNUT STREET, SUITE A
- **CITY:** OMAHA
- **STATE:** NE
- **ZIP:** 68144

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ANEW Medical, Inc.
- **DATE OF NAME CHANGE:** 20240624

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Redwoods Acquisition Corp.
- **DATE OF NAME CHANGE:** 20220127

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended September 30, 2025**

**or**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from <u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u> to <u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>**

**Commission file number: <u>001-41340</u>**

---

| |
|:---|
| **KLOTHO NEUROSCIENCES, INC.** |
| (Exact name of registrant as specified in its charter) |

---

---

| | |
|:---|:---|
| **Delaware** | **86-2727441** |
| (State or other jurisdiction of <br> incorporation or organization) | (I.R.S. Employer <br> Identification No.) |

---

1300 South Boulevard, Unit D

Charlotte, NC 28203

(Address of principal executive offices) (Zip Code)

<u>(833) 931-6330</u> <br> (Registrant's telephone number, including area code)

  <br> (Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock | KLTO | The Nasdaq Stock Market LLC |
| Warrants | KLTOW | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November 13, 2025, there were 72,536,722 shares of the registrant's common stock, $0.0001 par value, issued and outstanding.

**KLOTHO NEUROSCIENCES, INC.**

**FORM 10-Q FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2025**

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
| | | **Page** |
| [**PART I. FINANCIAL INFORMATION**](#KJ_001) | [**PART I. FINANCIAL INFORMATION**](#KJ_001) | 1 |
| ITEM 1. | [Financial Statements](#KJ_002) | 1 |
|  | [Condensed Consolidated Balance Sheets at September 30, 2025 (Unaudited) and December 31, 2024](#KJ_003) | 1 |
|  | [Unaudited Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2025 and 2024](#KJ_004) | 2 |
|  | [Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) for the Three and Nine Months Ended September 30, 2025 and 2024](#KJ_005) | 3 |
|  | [Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024](#KJ_006) | 4 |
|  | [Notes to Unaudited Condensed Consolidated Financial Statements](#KJ_007) | 5 |
| ITEM 2. | [Management's Discussion and Analysis of Financial Condition and Results of Operations](#KJ_008) | 21 |
| ITEM 3. | [Quantitative and Qualitative Disclosures about Market Risk](#KJ_009) | 24 |
| ITEM 4. | [Controls and Procedures](#KJ_010) | 24 |
| [**PART II. OTHER INFORMATION**](#KJ_011) | [**PART II. OTHER INFORMATION**](#KJ_011) | 26 |
| ITEM 1. | [Legal Proceedings](#KJ_012) | 26 |
| ITEM 1A. | [Risk Factors](#KJ_013) | 26 |
| ITEM 2. | [Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities](#KJ_014) | 26 |
| ITEM 3. | [Defaults Upon Senior Securities](#KJ_015) | 26 |
| ITEM 4. | [Mine Safety Disclosures](#KJ_016) | 26 |
| ITEM 5. | [Other Information](#KJ_017) | 26 |
| ITEM 6. | [Exhibits](#KJ_018) | 26 |
| [**SIGNATURES**](#KJ_019) | [**SIGNATURES**](#KJ_019) | 27 |

---

i

**PART I. FINANCIAL INFORMATION**

**Item 1. Financial Statements**

**KLOTHO NEUROSCIENCES, INC.**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

---

| | | |
|:---|:---|:---|
|  | **September 30,<br> 2025** | **December 31,<br> 2024** |
|  | **(Unaudited)** | |
| **ASSETS** | | |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $7348034 | $63741 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses | 86303 | 94070 |
| &nbsp;&nbsp;&nbsp;Subscriptions receivable | 339253 | - |
| **Total current assets** | 7773590 | 157811 |
| Other assets: |  |  |
| Licenses | 2251134 | 2251134 |
| Patents | 48420 | 48420 |
| Total other assets | 2299554 | 2299554 |
| **Total assets** | $10073144 | $2457365 |
| **LIABILITIES AND STOCKHOLDERS' EQUITY** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable | $34905 | $63686 |
| &nbsp;&nbsp;&nbsp;Accrued expenses | 57986 | 912095 |
| &nbsp;&nbsp;&nbsp;Notes payable to related parties | - | 31000 |
| &nbsp;&nbsp;&nbsp;Notes payable | - | 240753 |
| **Total current liabilities** | 92891 | 1247534 |
| &nbsp;&nbsp;&nbsp;Warrant liability | 53000 | 24486 |
| **Total liabilities** | 145891 | 1272020 |
| Commitments and contingencies (Note 10) |  |  |
| **STOCKHOLDERS' EQUITY** |  |  |
| Preferred stock, par value $0.0001, 100,000,000 shares authorized; 0 issued and outstanding as of September 30, 2025 and December 31, 2024 | - | - |
| Common stock, par value $0.0001, 1,000,000,000 shares authorized; 70,334,792 and 27,080,915 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | 7033 | 2708 |
| Additional paid-in capital | 29705817 | 11745436 |
| Accumulated deficit | (19785597) | (10562799) |
| **Total stockholders' equity** | 9927253 | 1185345 |
| **Total liabilities and stockholders' equity** | $10073144 | $2457365 |

---

See accompanying notes to the unaudited condensed consolidated financial statements.

**KLOTHO NEUROSCIENCES, INC.**

**UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the Three Months Ended<br> September 30,** | **For the Three Months Ended<br> September 30,** | **For the Nine Months Ended<br> September 30,** | **For the Nine Months Ended<br> September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Professional fees | $711169 | $865928 | $2372435 | $1634790 |
| &nbsp;&nbsp;&nbsp;General and administrative | 231404 | 52152 | 925563 | 63428 |
| &nbsp;&nbsp;&nbsp;Research and development | 271145 | - | 509845 | - |
| &nbsp;&nbsp;&nbsp;Share-based compensation | 639586 | 1952852 | 1525281 | 1990366 |
| Total operating expenses | 1853304 | 2870932 | 5333124 | 3688584 |
| Net operating loss | (1853304) | (2870932) | (5333124) | (3688584) |
| Other income (expense): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Interest Expense | (1177999) | (44956) | (3491961) | (60020) |
| &nbsp;&nbsp;&nbsp;Change in fair value of warrant liability | 79447 | 41022 | (28514) | 1325 |
| &nbsp;&nbsp;&nbsp;Loss on conversion of debt | - | (84560) | (448802) | - |
| &nbsp;&nbsp;&nbsp;Other income (expense) | 56271 | - | 79603 | (335830) |
| &nbsp;&nbsp;&nbsp;Unrealized loss on forward purchase contract | - | - | - | - |
| Total other income (expense) | (1042281) | (88494) | (3889674) | (394525) |
| Net loss before income taxes | (2895585) | (2959426) | (9222798) | (4083109) |
| Income taxes | - | **-**  | - | **-**  |
| Net loss | $(2895585) | $(2959426) | $(9222798) | $(4083109) |
| Net loss per share: Basic and Diluted | $(0.05) | $(0.18) | $(0.23) | $(0.25) |
| Weighted average common shares outstanding | 59416539 | 16688945 | 40414369 | 16588940 |

---

See accompanying notes to the unaudited condensed consolidated financial statements.

**KLOTHO NEUROSCIENCES, INC.**

**UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | | | **Preferred Stock** | **Preferred Stock** | | | | |
|  | **Common Stock** | **Common Stock** | **(Series B, C and D)** | **(Series B, C and D)** | | | | |
|  | **Shares** | **Amount** | **Shares** | **Amount** | **Additional**<br>**Paid-in**<br>**Capital** |<br>**Common Stock**<br>**to be Issued** |<br>**Accumulated**<br>**Deficit** | **Total**<br>**Stockholder's**<br>**Equity (Deficit)** |
| **Balance, January 1, 2025** | 27080915 | $2708 | &nbsp;&nbsp;&nbsp;&nbsp; - | $&nbsp;&nbsp;&nbsp;&nbsp; - | $11745436 | &nbsp;&nbsp;&nbsp;&nbsp; - | $(10562799) | $1185345 |
| &nbsp;&nbsp;&nbsp;Share-based compensation | - | - | - | - | 495500 | - | - | 495500 |
| &nbsp;&nbsp;&nbsp;Issuance of shares for note payable conversions | 1429717 | 143 | - | - | 466026 | - | - | 466169 |
| &nbsp;&nbsp;&nbsp;Issuance of equity warrants in connection with convertible debt |  | - |  | - | 679577 | - | - | 679577 |
| &nbsp;&nbsp;&nbsp;Termination of shares issued during merger under FPA agreement |  | - |  | - | 46100 | - | - | 46100 |
| &nbsp;&nbsp;&nbsp;Net loss | - | - | - | - | - | - | (2233982) | (2233982) |
| **Balance at March 31, 2025** | 28510632 | $2851 | - | $- | $13432639 | $- | $(12796781) | $638709 |
| &nbsp;&nbsp;&nbsp;Share-based compensation | 400000 | 40 | - | - | 390155 | - | - | 390195 |
| &nbsp;&nbsp;&nbsp;Issuance of common shares in connection with note conversions | 6583757 | 658 | - | - | 1225455 | - | - | 1226113 |
| &nbsp;&nbsp;&nbsp;Issuance of common shares in connection with warrant exercises | 10958681 | 1096 | - | - | 12924033 | - | - | 12925129 |
| &nbsp;&nbsp;&nbsp;Issuance of common shares in connection with stock subscriptions | 6250000 | 625 | - | - | 499375 | - | - | 500000 |
| &nbsp;&nbsp;&nbsp;Termination of shares issued during merger under FPA agreement |  | - |  | - | 94472 | - | - | 94472 |
| &nbsp;&nbsp;&nbsp;Issuance of Preferred B stock for cash | - | - | 500 | - | 500000 | - | - | 500000 |
| &nbsp;&nbsp;&nbsp;Deemed dividend - warrant modification |  | - |  | - | (1530910) | - | - | (1530910) |
| &nbsp;&nbsp;&nbsp;Net loss | - | - | - | - | - | - | (4093231) | (4093231) |
| **Balance at June 30, 2025** | 52703070 | $5270 | 500 | $- | $27535219 | $- | $(16890012) | $10650477 |
| &nbsp;&nbsp;&nbsp;Share-based compensation | 608691 | 61 | - | - | 639525 | - | - | 639586 |
| &nbsp;&nbsp;&nbsp;Conversion of Preferred B Shares to common stock | 6250000 | 625 | (500) | - | (625) | - | - | - |
| &nbsp;&nbsp;&nbsp;Discretionary share issuance | 2023031 | 202 | - | - | (202) | - | - | - |
| &nbsp;&nbsp;&nbsp;Debt conversion settlement | 2000000 | 200 | - | - | 1177800 | - | - | 1178000 |
| &nbsp;&nbsp;&nbsp;Subscription receivable |  | - |  | - | 349475 | - | - | 349475 |
| &nbsp;&nbsp;&nbsp;Forward share purchase contract | 6745000 | 675 | - | - | (675) | - | - | - |
| &nbsp;&nbsp;&nbsp;Sales of common stock through At-the-Market facility | 5000 | - | - | - | 5300 | - | - | 5300 |
| &nbsp;&nbsp;&nbsp;Net loss | - | - | - | - | - | - | (2895585) | (2895585) |
| **Balance at September 30, 2025** | 70334792 | $7033 | - | $- | $29705817 | $- | $(19785597) | $9927253 |
| **Balance, January 1, 2024\*** | 15130393 | $1513 | 120000 | $120 | $4493881 | - | $(3923677) | $571837 |
| &nbsp;&nbsp;&nbsp;Share-based compensation | - | - | - | - | 287251 | - | - | 287251 |
| &nbsp;&nbsp;&nbsp;Cancelled preferred B shares | - | - | (30000) | (30) | (38370) | - | - | (38400) |
| &nbsp;&nbsp;&nbsp;Stock dividends |  | - |  | - | - | - | (1911) | (1911) |
| &nbsp;&nbsp;&nbsp;Adjustment from reverse merger application\* |  | - |  | - | 213280 | - | - | 213280 |
| &nbsp;&nbsp;&nbsp;Net loss | - | - | - | - | - | - | (672044) | (672044) |
| **Balance at March 31, 2024\*** | 15130393 | $1513 | $90000 | $90 | $4956042 | $- | $(4597632) | $360013 |
| &nbsp;&nbsp;&nbsp;Share-based compensation | - | - | - | - | 37252 | 262 | - | 37514 |
| &nbsp;&nbsp;&nbsp;Retroactive application of merger | 548505 | 55 | (90000) | $(90) | $(1780834) | 304200 | 1911 | (1474758) |
| &nbsp;&nbsp;&nbsp;Public warrants assumed from SPAC |  | - |  | - | 488750 | - | (488750) | - |
| &nbsp;&nbsp;&nbsp;Private warrants assumed from SPAC |  | - |  | - | (22525) | - | - | (22525) |
| &nbsp;&nbsp;&nbsp;Net loss | - | - | - | - | - | - | (451639) | (451639) |
| **Balance at June 30, 2024** | 15678898 | $1568 | - | $- | $3678685 | $304462 | $(5536110) | $(1551395) |
| &nbsp;&nbsp;&nbsp;Conversion of Notes Payable | 3750617 | 375 | - | - | 4009634 | - | - | 4010009 |
| &nbsp;&nbsp;&nbsp;Warrant conversion | 130000 | 13 | - | - | - | - | - | 13 |
| &nbsp;&nbsp;&nbsp;Share-based compensation | 304000 | 30 | - | - | 1952821 | - | - | 1952851 |
| &nbsp;&nbsp;&nbsp;Other |  | - |  | - | 8518 | - | - | 8518 |
| &nbsp;&nbsp;&nbsp;Net loss | - | - | - | - | - | - | (2959426) | (2959426) |
| **Balance at September 30, 2024** | 19863515 | $1986 | - | $- | $9649658 | $304462 | $(8495536) | $1460570 |

---

\* Note: as a result of the business combination as recast, the shares of the Company's common stock prior to the Business Combination (refer to Note 1) have been retrospectively recast to reflect the change in the capital structure as a result of the Business Combination on 6/21/24.

See accompanying notes to the unaudited condensed consolidated financial statements.

**KLOTHO NEUROSCIENCES, INC.**

**UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

---

| | | |
|:---|:---|:---|
|  | **For the Nine Months Ended<br> September 30,** | **For the Nine Months Ended<br> September 30,** |
|  | **2025** | **2024** |
| **CASH FLOWS FROM OPERATING ACTIVITIES:** |  |  |
| **Net loss** | $(9222798) | $(4083109) |
| **Adjustments to reconcile net loss to net cash used in operating activities:** |  |  |
| &nbsp;&nbsp;&nbsp;Changes in fair value of warrant liability | 28514 | (1325) |
| &nbsp;&nbsp;&nbsp;Commitment fee |  | 250000 |
| &nbsp;&nbsp;&nbsp;Impairment on intangible assets |  |  |
| &nbsp;&nbsp;&nbsp;Interest expense | 3505712 |  |
| &nbsp;&nbsp;&nbsp;Loss on conversion of note payable | 448802 |  |
| &nbsp;&nbsp;&nbsp;Stock-based compensation | 1525281 | 1990366 |
| **Changes in operating assets and liabilities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses | 7767 | (99910) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subscriptions receivable | 10222 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | (28781) | 19870 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses | (854109) | 557839 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tax payable |  | (568111) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Related party payable | (31000) | (128000) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other Liabilities | - | 60022 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in operating activities | $(4610390) | $(2002358) |
| **CASH FLOWS FROM INVESTING ACTIVITIES:** |  |  |
| &nbsp;&nbsp;&nbsp;Acquisition of patents |  |  |
| &nbsp;&nbsp;&nbsp;Acquisition of drug license | - | (123497) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in (provided by) investing activities | $- | $(123497) |
| **CASH FLOWS FROM FINANCING ACTIVITIES:** |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from convertible promissory note, net of issuance cost | 2150000 | 1000000 |
| &nbsp;&nbsp;&nbsp;Proceeds from sales of stocks and warrants, net | 11394218 | 175000 |
| &nbsp;&nbsp;&nbsp;Proceeds from stock subscriptions | 500000 |  |
| &nbsp;&nbsp;&nbsp;Proceeds from sale of preferred B shares | 500000 |  |
| &nbsp;&nbsp;&nbsp;Payments on notes payable | (2730182) |  |
| &nbsp;&nbsp;&nbsp;Payments for deferred financing costs | (25000) |  |
| &nbsp;&nbsp;&nbsp;Proceeds from FPA settlement | 140572 |  |
| &nbsp;&nbsp;&nbsp;Payments on financed director and officer insurance | (40225) |  |
| &nbsp;&nbsp;&nbsp;Proceeds from At-the-Market sales of common shares | 5300 |  |
| &nbsp;&nbsp;&nbsp;Proceeds from related party loans |  | 100000 |
| &nbsp;&nbsp;&nbsp;Proceeds from shareholders |  | 120000 |
| &nbsp;&nbsp;&nbsp;Merger proceeds net of transaction cost | - | 778942 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by financing activities | $11894683 | $2173942 |
| **NET CHANGE IN CASH** | 7284293 | 48087 |
| &nbsp;&nbsp;&nbsp;Cash - Beginning of period | 63741 | 2808 |
| &nbsp;&nbsp;&nbsp;Cash - End of period | $7348034 | $50895 |
| **SUPPLEMENTAL NON-CASH FINANCING AND INVESTING ACTIVITIES:** |  |  |
| &nbsp;&nbsp;&nbsp;Note payable settled with issuance of common stock | $1473441 | $5258270 |
| &nbsp;&nbsp;&nbsp;Reversal of OID | $681506 | $- |
| &nbsp;&nbsp;&nbsp;Non-cash directors and officers insurance | $- | $154500 |
| &nbsp;&nbsp;&nbsp;Non-cash PIPE Funds used for merger transaction close | $- | $2950000 |
| &nbsp;&nbsp;&nbsp;Commitment fee paid in stock | $- | $250000 |
| &nbsp;&nbsp;&nbsp;Assumed income tax payable from merger | $- | $568111 |
| &nbsp;&nbsp;&nbsp;Assumed warrant liability from merger | $- | $22525 |
| &nbsp;&nbsp;&nbsp;Interest payable settled with issuance of common stock | $57641 | $60022 |
| &nbsp;&nbsp;&nbsp;Repurchase of warrants | $679577 | $- |
| &nbsp;&nbsp;&nbsp;Issuance of warrants | $(679577) | $- |
| &nbsp;&nbsp;&nbsp;Warrant conversion | $- | $96200 |
| **SUPPLEMENTAL CASH FLOW INFORMATION:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest Paid | $79153 | $2460 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Taxes Paid | $- | $- |

---

See accompanying notes to the unaudited condensed consolidated financial statements.

**KLOTHO NEUROSCIENCES, INC.**

**NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**NOTE 1 — ORGANIZATION AND BUSINESS DESCRIPTION**

Klotho Neurosciences, Inc. ("The Company" or "Klotho"), formerly known as ANEW Medical, Inc., develops essential medicines for the treatment of chronic diseases – cancer, cardiovascular, and neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform that uses a gene therapy approach to introduce a therapeutic protein called "Klotho" inside the body to treat neurodegenerative diseases.

On September 12, 2022, the Company acquired five market-approved anti-cancer drugs approved for sale in Germany. The Market Authorizations (MA's) are for four of the drugs that comprise the "FOLFOX" and "FOLFIRI" multi-drug regimens used in treatment of metastatic colorectal and gastric cancer and in two of the drugs that are used to treat metastatic lung cancer. The drugs are important in the treatment of many solid tumors in both childhood and adult cancers. Previously, the Company acquired two off-patent bio generic antibodies from Reliance Life Sciences (RLS), the life science arm of Reliance Industries Pvt Ltd. of Navi Mumbai, India.

Effective July 24, 2024, the Company changed its legal name from ANEW Medical, Inc. to Klotho Neurosciences, Inc. This name change was approved by the Company's Board of Directors to better reflect the strategic focus of its proprietary products. Throughout these financial statements, references to the "Company" refer to Klotho Neurosciences, Inc., formerly known as ANEW Medical, Inc (ANEW). Under certain circumstances, references to ANEW have remained useful when describing the sequence of events that occurred during the merger between Redwoods and ANEW.

*Business Combinations* 

As of May 30, 2023, Redwoods Acquisition Corp., a Delaware corporation and a special purpose acquisition company ("Redwoods"), ANEW Medical Sub, Inc., a Wyoming corporation ("Merger Sub") and ANEW Medical, Inc., a Wyoming corporation ("ANEW") entered into a Business Combination Agreement, which was amended as of November 4, 2023 (the "Business Combination Agreement"). On June 21, 2024 (the "Closing Date"), Merger Sub merged with and into ANEW, with ANEW continuing as the surviving corporation and as a wholly owned subsidiary of Redwoods (the "Business Combination"). In connection with the Business Combination, on June 21, 2024, Redwoods filed its Second Amended Certificate of Incorporation with the Delaware Secretary of State and adopted the amended and restated bylaws (the "Amended and Restated Bylaws"), which replaced Redwoods' Charter and Bylaws in effect as of such time. In connection with the closing of the Business Combination (the "Closing"), Redwoods changed its name to "ANEW Medical, Inc."

For accounting purposes, the transactions contemplated by the Business Combination are treated as a reverse acquisition and, as such, the historical financial statements of the accounting acquirer ANEW (Wyoming) will become the historical financial statements of the Company. Under this method of accounting, Redwoods was treated as the acquired company for financial reporting purposes. Accordingly, for accounting purposes, the Merger was treated as the equivalent of the Company issuing shares for the net assets of Redwoods, accompanied by a recapitalization. The net assets of Redwoods were stated at historical cost with no goodwill or other intangible assets recorded.

*Recapitalization* 

In connection with the merger, the Company issued six million shares in exchange for all the outstanding shares of ANEW. At $10 per Redwood's share, the valuation of ANEW was $60 million.

Immediately after giving effect to the Business Combination, 15,130,393 shares of Company Common Stock were outstanding, from which 2,875,000 remained in escrow for the Redwoods founders. In addition, there were 12,030,000 warrants immediately exercisable and composed of 11,500,000 public warrants and 530,000 private warrants. Following the Closing, on June 21, 2024, the Company's Common Stock and Warrants began trading on the Nasdaq under the symbols "WENA" and "WENAW," respectively. The Public Units of Redwoods automatically separated into the component securities upon consummation of the Business Combination and, as a result, no longer trade as a separate security. Further, upon the closing of the Business Combination on June 21, 2024, the Company received approximately $181,339 in net cash proceeds.

At Closing, pursuant to the terms of the Business Combination Agreement and after giving effect to the redemptions of shares of Redwoods Common Stock:

● The total consideration paid at Closing (the "Merger Consideration") by Redwoods to ANEW Medical, Inc. security holders was 6,000,000 shares of the Company common stock valued at $60 million (the "Consideration Shares"), based on an implied ANEW equity value of $60,000,000 valued at $10 per share;

● Each share of ANEW Medical Common Stock, if any, that was owned by Redwoods, Merger Sub, ANEW Medical, Inc. or any other affiliate of Redwoods immediately prior to the effective time of the Merger (the "Effective Time") was automatically cancelled and retired without any conversion or consideration;

● Each share of Merger Sub common stock, par value $0.0001 per share ("Merger Sub Common Stock"), issued and outstanding immediately prior to the Effective Time was converted into one newly issued share of Common Stock of the Surviving Corporation.

In connection with the Merger, the Company entered into a convertible promissory note and Securities Purchase Agreement ("SPA") with certain accredited investors (the "Redwoods PIPE Investors") for an aggregate of 750,000 shares (bonus free trading shares and restricted shares issued at closing), with each unit consisting of one share of Company common stock (the "PIPE Shares") for an aggregate purchase price of $2,000,000 (the "Redwoods PIPE Financing"). Upon the closing of the Redwoods PIPE Financing (which closed in connection with the closing of the Merger), the $2,000,000 were used by the Company to settle transaction costs. The Company received approximately $181,339 in net cash proceeds and recorded a receivable of $50,000 from the Redwoods PIPE Financing funds. The $2,000,000 note has been converted into shares and considered as paid in full as of December 31, 2024.

In connection with the Merger, the Company entered convertible promissory note and Securities Purchase Agreement ("SPA") with certain accredited investors (the "ANEW PIPE Investors") for an aggregate of 854,257 units (bonus free trading shares and restricted shares issued at closing), with each unit consisting of one share of Company common stock (the "PIPE Shares") for an aggregate purchase price of $2,000,000 (the "ANEW PIPE Financing"). Upon the closing of the ANEW PIPE Financing (which closed in connection with the closing of the Merger), $1,000,000 was used by the Company to settle transaction costs. The Company received approximately $950,000 in cash proceeds and recorded a receivable of $50,000 from the ANEW PIPE Financing funds. The $2,000,000 note has been converted into shares and considered as paid in full as of December 31, 2024.

Certain ANEW stockholders may be entitled to up to an additional 2,000,000 shares of Company Common Stock (the "*Contingent Consideration Shares*"), upon the following conditions being met:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) 1,000,000 Contingent Consideration Shares upon the Company's common stock achieving a closing price equal to or exceeding $15.00 for 10 trading days within a 20-day trading period in the first three years following the Closing; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) 1,000,000 Contingent Consideration Shares upon the Company's common stock achieving a closing price equal to or exceeding $20.00 for 10 trading days within a 20-day trading period in the first five years following the Closing.

In accordance with guidance applicable to these circumstances, the equity structure has been restated in all comparable periods up to June 21, 2024 and reflected as such as of December 31, 2024, to reflect the number of shares of the Company's common stock, $0.0001 par value per share, issued to ANEW's stockholders in connection with the merger. As such, the shares and corresponding capital amounts and earnings per share related to ANEW's common stock prior to the merger have been retroactively restated as shares reflecting the exchange ratio established in the merger.

For accounting purposes, the Merger was treated as the equivalent of the Company issuing shares for the net assets of Redwoods, accompanied by a recapitalization. The net assets of Redwoods were stated at historical cost with no goodwill or other intangible assets recorded. In connection with the Merger, in addition to the warrants, ANEW Medical assumed $589,081 in cash and $568,111 in income tax payable. The income tax payable of $568,111 was settled in full as of December 31, 2024 from the assumed $589,081 cash.

**NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

*Going Concern*

The accompanying unaudited condensed consolidated financial statements have been prepared as if the Company will continue as a going concern. The Company has incurred significant operating losses and negative cash flows from operations since inception. As of September 30, 2025, the Company had cash and cash equivalents of approximately $7.3 million and an accumulated deficit of approximately $19.8 million. The Company has incurred recurring losses, has experienced recurring negative operating cash flows, and requires significant cash resources to execute its business plans. The Company is dependent on obtaining additional working capital funding from the sale of equity and/or debt securities in order to continue to execute its development plans and continue operations. Without additional funding, there is substantial doubt about the Company's ability to continue as a going concern for twelve months from the date of these financial statements.

*Basis of Presentation and Principles of Consolidation*

The Company prepares its consolidated financial statements in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and pursuant to the rules and regulations of the SEC. The Company prepared the Financial Statements, without audit, pursuant to the rules and regulations of the SEC applicable to quarterly reporting on Form 10-Q and reflect, in management's opinion, all adjustments necessary to present fairly the financial information. All such adjustments are of a normal recurring nature. Certain information and footnote disclosures normally included in financial statements, prepared in accordance with generally accepted accounting principles, have been consolidated or omitted as permitted by such rules and regulations. These Financial Statements should be read in conjunction with the consolidated financial statements and related notes included in the 2024 Annual Report. Results of operations for interim periods are not necessarily indicative of annual results.

*Reclassification*

Certain prior year amounts have been reclassified for comparative purposes to conform to the current-year financial statement presentation. These reclassifications had no effect on previously reported results of operations and were not material.

*Emerging Growth Company*

The Company is an "emerging growth company," as defined in Section 2(a) of the Securities Act of 1933, as amended (the "Securities Act"), as modified by the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company's financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period, difficult or impossible because of the potential differences in accounting standards used.

*Use of Estimates*

The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires the Company's management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.

 

*Cash and Cash Equivalents*

Cash and cash equivalents represent cash on hand, demand deposits, and other short-term highly liquid investments placed with banks, which have original maturities of three months or less and are readily convertible to known amounts of cash.

 

*Concentration of Credit Risk*

Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. As of September 30, 2025, the Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.

*Fair Value of Financial Instruments*

The assets and liabilities are valued using a fair market basis as defined in the Financial Accounting Standards Board ("FASB") Accounting Standards Update ("ASU") ASC 820, Fair Value Measurement. Fair value is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date. The Company uses a three-level hierarchy established by the FASB that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques (market approach, income approach and cost approach). The levels of the fair value hierarchy are described below:

---

| | |
|:---|:---|
| Level 1: | Quoted prices in active markets for identical assets or liabilities. |
| Level 2: | Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. |
| Level 3: | Unobservable inputs with little or no market data available, which require the reporting entity to develop its own assumptions. |

---

The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. Financial assets and liabilities are classified in their entirety based on the most conservative level of input that is significant to the fair value measurement.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Fair value measurements at reporting date using:** | **Fair value measurements at reporting date using:** | **Fair value measurements at reporting date using:** | **Fair value measurements at reporting date using:** |
|  | **Fair value** | **Quoted prices in <br> active markets <br> for identical<br> assets or<br> liabilities (Level 1)** | **Significant<br> other<br> observable<br> inputs <br> (Level 2)** | **Significant<br> unobservable inputs <br> (Level 3)** |
| Assets: |  |  |  |  |
| Cash equivalents, September 30, 2025 | $7129434 | $7129434 | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - | $- |
| Cash equivalents, December 31, 2024 | $- | $- | $- | $- |
| Liabilities: |  |  |  |  |
| Representative warrant liabilities, September 30, 2025 | $53000 | $- | $- | $53000 |
| Representative warrant liabilities, December 31, 2024 | $24486 | $- | $- | $24486 |

---

The following tables present a reconciliation of the Level 3 Representative Warrants liabilities:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended<br> September 30,** | **Three Months Ended<br> September 30,** |
|  | **2025** | **2024** |
| Representative warrant liabilities, July 1 | $132447 | $62222 |
| Change in fair value | (79447) | (41022) |
| Representative warrant liabilities, September 30 | $53000 | $21200 |

---

---

| | | |
|:---|:---|:---|
|  | **Nine Months Ended<br> September 30,** | **Nine Months Ended<br> September 30,** |
|  | **2025** | **2024** |
| Representative warrant liabilities, January 1 | $24486 | $- |
| Issuances/Assumptions | - | 22525 |
| Change in fair value | 28514 | (1325) |
| Representative warrant liabilities, September 30 | $53000 | $21200 |

---

*Intangible Assets*

The Company's intangible assets consist of acquired medical licenses and patents.

The Company acquires medical licenses for the treatment of medical conditions to market and sell in the future. The initial asset cost is the cost to acquire the license. Once in use, the Company amortizes the license cost over the useful life using the straight-line method. As part of the licensing agreements, the Company acquires patents and records the cost to acquire patents as the initial asset cost. Once the patents are approved and in use, assuming no litigation expenses, the Company amortizes the patent cost over the useful life using the straight-line method. The amortization period will not exceed the lifespan of the protection afforded by the patent. If the expected useful life of the patent is even shorter, the Company will use the useful life for amortization purposes. Thus, the shorter of a patent's useful life or legal life will be used for the amortization period.

*Impairment of Long-Lived and Intangible Assets*

The Company assesses the impairment of long-lived and intangible assets periodically, or at least annually, and whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors considered important, which could trigger an impairment review, include the following: significant underperformance relative to historical or projected future cash flows; significant changes in the manner of use of the assets or the strategy of the overall business; and significant negative industry trends. When management determines that the carrying value of long-lived and intangible assets may not be recoverable, impairment is measured as the excess of the assets' carrying value over the estimated fair value. Management is not aware of any other impairment charges that may currently be required; however, the Company cannot predict the occurrence of events that might adversely affect the reported values in the future. On an annual basis, the Company tests the long-lived and intangible assets for impairment based on the projected net present value of cash flows for each asset. Prior to the annual impairment test, if circumstances change and a long-lived or intangible asset is deemed impaired, an impairment loss will be immediately recognized in the statements of operations. At December 31, 2024, the date of the last impairment test, the Company determined that the license related to Teleost Biopharmaceutic, LLC was impaired and recognized an impairment expense of $10,000 as of December 31, 2024. The Company determined that the estimated fair value of all other intangible assets exceeded their carrying value, indicating no impairment.

 

 

*Revenue Recognition*

The Company is in a pre-revenue state and does not generate revenue. When the Company commences to derive revenue, those contracts will be accounted in accordance with ASU 2014-09, Revenue from Contracts with Customers (Topic ASC 606).

*Income Taxes*

The Company uses the asset and liability method of accounting for income taxes in accordance with ASU 740, "Income Taxes". Under this method, income tax expense is recognized as the amount of: (i) taxes payable or refundable for the current year and (ii) future tax consequences attributable to differences between the consolidated financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of available evidence it is more likely than not that some portion or all of the deferred tax assets will not be realized.

The Company is subject to Income tax filings requirements in U.S. federal and various state jurisdictions. The Company's tax returns for years from 2022, 2023 and 2024 are subject to U.S. federal, state, and local income tax examinations by tax authorities.

The Company reports income tax related interest and penalties within the income tax line item on the consolidated statements of operations. The Company likewise reports the reversal of income tax-related interest and penalties within such line item to the extent the Company resolves the liabilities for uncertain tax positions in a manner favorable to the accruals.

*Net Loss Per Share (Basic and Diluted)*

Basic net loss per share is computed by dividing net loss by the weighted average number of shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of shares outstanding, plus the number of additional shares that would have been outstanding if the common share equivalents had been issued, if dilutive.

The following table details the net loss per share calculation, reconciles between basic and diluted weighted average shares outstanding, and presents the potentially dilutive shares that are excluded from the calculation of the weighted average diluted common shares outstanding, because their inclusion would have been anti-dilutive:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the Three Months Ended** | **For the Three Months Ended** | **For the Nine Months Ended** | **For the Nine Months Ended** |
|  | **September 30,** | **September 30,** | **September 30,** | **September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Numerator: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net loss | $(2895585) | $(2959426) | $(9222798) | $(4083109) |
| &nbsp;&nbsp;&nbsp;Weighted-average common shares outstanding, basic and diluted | 59416539 | 16688945 | 40414369 | 16588940 |
| &nbsp;&nbsp;&nbsp;Basic and diluted loss per share | $(0.05) | $(0.18) | $(0.23) | $(0.25) |

---

The following common share equivalents are excluded from the calculation of weighted average common shares outstanding, because their inclusion would have been anti-dilutive:

---

| | | |
|:---|:---|:---|
|  | **As of September 30,** | **As of September 30,** |
|  | **2025** | **2024** |
| Warrants | 5071319 | 12030000 |
| Total potentially dilutive shares | 5071319 | 12030000 |

---

*Research and Development Cost*

Research and development (R&D) costs are expensed as incurred. R&D costs are related to the Company's internally funded development of the Company medical licenses and patents. The Company R&D costs were $271,145 and $509,845 for the three and nine months ended September 30, 2025, respectively, and $0 for the three and nine months ended September 30, 2024.

*Share-based Compensation*

The Company accounts for share-based compensation in accordance with the fair value recognition provisions of the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") No. 718 and No. 505. The Company issues restricted stock and stock options to employees and consultants for their services. Costs for these transactions are measured at the fair value of the equity instruments issued at the date of grant. These shares are considered fully vested and the fair market value is recognized as an expense in the period granted. The Company recognized consulting expenses and a corresponding increase to additional paid-in-capital related to stock issued for services. For agreements requiring future services, the consulting expense is to be recognized ratably over the requisite service period.

The Company recorded share-based compensation of $639,586 and $1,952,852 for the three months ended September 30, 2025, and 2024, respectively. The Company recorded share-based compensation of $1,525,281 and $1,990,366 for the nine months ended September 30, 2025 and 2024, respectively.

 

*Warrants*

As of September 30, 2025, the fair value of the Representative Warrant liabilities was $53,000 based on the closing price of the warrants on The Nasdaq Capital Market. The fair value of the Representative Warrants was approximately $0.10 per Representative Warrant as of September 30, 2025, which was based on the relative fair value to the Public Warrants. During the three months ended September 30, 2025, the fair value of the Representative warrants decreased by $79,447. During the nine months ended September 30, 2025, the fair value of the Representative warrants increased by $28,514.

*Related Parties*

The Company follows subtopic 850-10 of the FASB Accounting Standards Codification for the identification of related parties and disclosure of related party transactions.

Pursuant to Section 850-10-20 the related parties include (a) affiliates of the Company; (b) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; (c) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; (d) principal owners of the Company; (e) management of the Company; (f) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and (g) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.

The financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: (a) the nature of the relationship(s) involved; (b) description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; (c) the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and (d) amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.

*Segment Information*

Operating segments are defined as components of an enterprise for which separate discrete information is available for evaluation by the Chief Operating Decision Maker ("CODM") or decision-making group in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business as one operating and reporting segment, which is the business of research and development of essential medicines for the treatment of chronic diseases – cancer, cardiovascular, and neurodegenerative disorders. See Note 11 Segment Information for additional information.

*Recent Accounting Pronouncements*

In June 2016, the FASB issued ASU 2016-13, *Financial Instruments – Credit Losses,* which requires entities to estimate all expected credit losses for financial assets measured at amortized cost basis, including trade receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The Company adopted this guidance on January 1, 2023. The adoption of this accounting standard did not have an impact on the Company's consolidated financial statements as the Company is in a pre-revenue state and does not generate revenue and has no receivables from third party.

In November 2023, the FASB issued ASU 2023-07, *Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures*, which requires incremental disclosure of segment information on an interim and annual basis. This ASU is effective for public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Retrospective application to all prior periods presented in the financial statements is required for public entities. The Company adopted ASU 2023-07 as of January 1, 2024, which resulted in additional disclosures of significant segment expenses and other segment items as well as incremental qualitative disclosures.

**NOTE 3 — PREPAID EXPENSES**

Prepaid expenses consist of prepayment of the premium on Directors and Officers insurance, NASDAQ annual fees, association membership fees, and Delaware franchise taxes. As of September 30, 2025 and December 31, 2024, prepaid expenses totaled $86,303 and $94,070, respectively, in the accompanying condensed consolidated balance sheets.

**NOTE 4 — INTANGIBLE ASSETS**

 

Intangible assets consisted of the following:

---

| | | |
|:---|:---|:---|
| **Intangible Assets** | **September 30, <br> 2025** | **December 31, <br> 2024** |
| Licenses |  |  |
| &nbsp;&nbsp;&nbsp;Non-Exclusive License Agreement | $179821 | $179821 |
| &nbsp;&nbsp;&nbsp;Various generic drugs | 736983 | 736983 |
| &nbsp;&nbsp;&nbsp;Four generic drugs (Encore) | 1308270 | 1308270 |
| &nbsp;&nbsp;&nbsp;Needleless Syringe License | 26060 | 26060 |
| &nbsp;&nbsp;&nbsp;Patents | 48420 | 48420 |
| Total intangible assets | $2299554 | $2299554 |

---

Intangible assets are as follows:

●  ***Non-Exclusive License Agreement ($179,821)*** – On March 5, 2023, the Company signed a Non-Exclusive License Agreement with Heidelberg University to grant non-exclusive rights to various licenses owned and under development by the university. The licenses include the use of modified AAV capsid polypeptides for treatment of muscular diseases. The terms include a €50,000 ($56,325) fee for signing the agreement and €100,000 ($112,650) payment within 60 days of the anniversary of signing the agreement. The Company will pay €1,000,000 ($1,126,500) for each assignment of a right to a license owned by the university. For new licenses, the Company will make standard commercial development-based milestone payments for the various stages of license development and regulatory approval. The Company will make 2% royalty payments by January 31<sup>st</sup> each year during the term of the agreement for each licensed product for the proceeding calendar year. The value of the licenses was $179,821 at September 30, 2025 and December 31, 2024, respectively.

●  ***Various Generic Drugs ($736,983)*** - During 2015, the Company acquired two licenses for biosimilar biologic therapies to treat cancer and autoimmune diseases. The value of the licenses was $736,983 at September 30, 2025 and December 31, 2024, respectively.

●  ***Four Generic Drugs (Encore) ($1,308,270)*** – On September 12, 2022, the Company acquired four market-approved anti-cancer drugs approved for sale in Germany for $1,308,270. The purchase price represents the fair value of the intangible asset based on the net present value of the projected gross profit to be generated by the licenses. The value of the licenses was $1,308,270 at September 30, 2025 and December 31, 2024.

● **Needleless Syringe License ($26,060)** – On December 1, 2023, the Company signed a license agreement with TransferTech Sherbooke for the rights to develop and commercialize the technology of a "Needleless Syringe." Under the terms of the agreement, the Company paid a $26,060 upfront fee and royalty fees on the license income. The Company has not commenced developing the technology. The amount paid under the agreement is $26,060 at September 30, 2025 and December 31, 2024, respectively.

● **Patents ($48,420)** – Through its licensing arrangements, the Company acquires the right to patents for Alzheimer, ALS, and other items. Once the patents are declared effective, patents are amortized using the straight-line method over their estimated useful lives or statutory lives, whichever is shorter, and will be reviewed for impairment upon any triggering event that may impact the assets' ultimate recoverability as prescribed under the guidance related to impairment of long-lived assets. Costs incurred to acquire patents, including legal costs, are also capitalized as long-lived assets and amortized on a straight-line basis with the associated patent. The patent value, which is part of licenses in the accompanying condensed consolidated balance sheet, as of September 30, 2025 and December 31, 2024, was $48,420, respectively.

● **Exclusive World-wide License Agreement** - On January 24, 2022, the Company signed an exclusive, world-wide License Agreement with the University of Barcelona for a cell and/or gene therapy that has shown compelling activity in animal models of human Alzheimer's disease and amyotrophic lateral sclerosis ("ALS" or "Lou Gehrig's disease"). The gene therapy will also be applied to age-related diseases and rare ("Orphan") diseases. Beginning on December 15, 2022, the annual license fee is 10,000 Euros. In addition, the Company will pay a Royalty equal to 3% of net sales of finished products once the license is in use. As of September 30, 2025 and December 31, 2024, the Company owed $0 under the agreement.

During the three months ended September 30, 2025, the Company purchased a license for $150,000 to be assessed for use in manufacturing the Company's KLTO-202 product, targeting amyotrophic lateral sclerosis and other motor neuron diseases of mankind. As the effectiveness of the particular license technology to manufacture KLTO-202 is undetermined, the $150,000 was expensed as research and development within the consolidated statements of operations for the three months ended September 30, 2025.

These licenses and patents are not currently in use as the Company is in pre-revenue stage. Once these licenses are in use, the licenses will be amortized over its useful life. The Company expects to utilize these licenses and patents later in the year.

**NOTE 5 — ACCOUNTS PAYABLE AND ACCRUED EXPENSES**

Accounts payable and accrued expenses consist of professional fees. The accounts payable and accrued expenses as of September 30, 2025 and December 31, 2024 were $92,891 and $975,781, respectively, in the accompanying condensed consolidated balance sheet.

**NOTE 6 — NOTES PAYABLE TO RELATED PARTIES** 

Notes payable to related parties consisted of the following:

---

| | | |
|:---|:---|:---|
|  | **September 30, <br> 2025** | **December 31,<br> 2024** |
| May 2024 and December 2023 - $7,000 and $24,000 original amount bearing a one-time interest fee of $2,460 due upon demand. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - | 31000 |
| Total notes payable to related parties | $- | $31000 |

---

***May 2024 and December 2023 ($7,000 and $24,000)*** – On December 12, 2023, the Company issued a promissory note to a member of management. The promissory note accrued interest at a one-time interest fee of $2,460, which was paid off in full as of September 30, 2025. The unpaid principal balance was $0 and $31,000 at September 30, 2025 and December 31, 2024, respectively.

**NOTE 7 — NOTES PAYABLE**

*Upper Clapton Convertible Promissory Note*

On September 12, 2022, the Company issued a $1,308,270 promissory note used to acquire four market-approved anti-cancer drugs. See *<u>Note 4 – Intangible Assets</u>* for further discussion. The promissory note bore interest at 6% and had a maturity date of June 30, 2023. Pursuant to the agreement, the interest stopped accruing at June 30, 2023. As of December 31, 2023, the Company made interest payments of $78,496 to fully satisfy the interest obligation under the promissory note. The note was converted into the Company's common shares and fully settled as part of the merger that closed on June 21, 2024. The outstanding principal balance of the note was $0 at September 30, 2025 and December 31, 2024, respectively.

*Redwoods PIPE Investor Convertible Promissory Note*

On March 4, 2024, in connection with the Merger, Public ANEW entered into a convertible promissory note that bore an interest of 10% and Securities Purchase Agreement ("SPA") with certain accredited investors (the "Redwoods PIPE Investors") for an aggregate purchase price of up to $2,000,000 (the "Redwoods PIPE Financing"), which included 750,000 bonus shares of common stock. Upon the closing of the Redwoods PIPE Financing (funded and closed in connection with the closing of the Merger on June 21, 2024), which totaled $1,950,000, of which $1,768,661 was used by the Company to settle transaction costs. The Company received approximately $181,339 in net cash proceeds. The note and related interest were converted into the Company's common shares and fully settled as of September 30, 2024. The outstanding principal balance as of September 30, 2025 and December 31, 2024 was $0, respectively.

*ANEW PIPE Investors Convertible Promissory Note*

On April 22, 2024, prior to the closing of the Business Combination Agreement, ANEW Medical (Wyoming) entered into a convertible promissory note that bore an interest of 10% and Securities Purchase Agreement ("SPA") with certain accredited investors (the "ANEW PIPE Investors") for an aggregate purchase price of up to $2,000,000 (the "ANEW PIPE Financing"), which included 900,000 bonus shares of common stock. Upon the closing of the ANEW PIPE Financing (funded and closed in connection with the closing of the Merger on June 21, 2024), which totaled $1,950,000 initially, of which $1,000,000 was used by the Company to settle transaction costs. The Company received approximately $1,000,000 in cash proceeds during the years ended December 31, 2024. The note and related interest were converted into the Company's common shares and fully settled as of September 30, 2024. The outstanding principal balance as of September 30, 2025 and December 31, 2024 was $0, respectively.

*Austria Capital LLC Convertible Promissory Note*

On December 4, 2024, the Company entered into a convertible promissory note ("the note") with a principal amount of $1,200,000 pursuant to the terms of a securities purchase agreement by and between the Company, as issuer, and Austria Capital LLC, as investor ("Investor"). The maturity date of the note is December 4, 2025. The note bears no interest, has an original issue discount of $200,000 and deferred financing costs related to legal fees of $73,000. In addition, the note offered the investor an equity inducement of two million shares, which were issued to the Investor and valued at $978,000. The total of the original issue discount, deferred financing costs and equity inducement, exceeded the principal balance by approximately $51,000, which was expensed as an interest expense on the condensed consolidated statements of operations. Total amortization of these costs recognized as contra-liabilities to be presented net with the principal liability on the condensed consolidated balance sheets was $100,000 at December 31, 2024.

At any time after the approval by the Company's stockholders, at the option of the Investor, the outstanding principal amount of the note or any portion thereof, is convertible into shares of the Company's common stock at a price of $0.25 per share; provided that no conversions can take place if the Investor then owns more than 4.99% of the number of the shares of the Company's common stock outstanding. The conversion price is subject to adjustment in connection with certain transactions, including stock splits or combinations and the like.

Pursuant to the terms of the Sale Purchase Agreement, the Company issued to the Investor a total of 2,000,000 shares of the Company's common stock as an inducement to the Investors to purchase the note. Such shares were issued in reliance upon Section 4(a)(2) of the Securities Act in a transaction not involving any public offering.

The note was paid off in full as of September 30, 2025 and net liability as of September 30, 2025 and December 31, 2024 was approximately $0 and $100,000, respectively.

During the three months ended September 30, 2025, the Company issued 2,000,000 additional shares in connection with settlement of the note, resulting in interest expense of $1,178,000.

*Red Road Holdings Promissory Note* 

On December 10, 2024, the Company signed a loan agreement with Red Road Holdings in the amount of $203,324, including guaranteed interest of $21,784. In connection with the note issuance, an original issue discount of $25,040 was recognized as well as deferred financing costs related to legal fees of $6,500. The net liability presented on the condensed consolidated balance sheet was $181,722 as of June 30, 2024 as a result of amortization of $17,515 recognized in interest expense on the condensed consolidated statement of operations for the year ended September 30, 2025. As of September 30, 2025, the net liability presented on the condensed consolidated balance sheet was $0 as the note was paid off in full, including interest expense composed of $21,784 interest, $25,040 original issue discount, and related legal fees of $6,500.

On January 3, 2025, the Company signed a loan agreement with Red Road Holdings in the amount of $137,715, including guaranteed interest of $14,755. In connection with the note issuance, an original issue discount of $16,960 was recognized as well as deferred financing costs related to legal fees of $6,000. The promissory note is due on November 15, 2025. The note is convertible to shares in the event of default. As of September 30, 2025, the net liability presented on the condensed consolidated balance sheet was $0 as the note was paid off in full, including interest expense composed of $14,755 interest, $16,960 original issue discount, and related legal fees of $6,000.

On April 4, 2025, the Company signed a loan agreement with Red Road Holdings in the amount of $106,534, including guaranteed interest of $11,414. In connection with the note issuance, an original issue discount of $13,120 was recognized. as well as deferred financing costs related to legal fees of $7,000. The promissory note is due on January 30, 2026. The note is convertible to shares in the event of default. As of September 30, 2025, the net liability presented on the condensed consolidated balance sheet was $0 as the note was paid off in full, including interest expense composed of $11,414 interest, $13,120 original issue discount, and related legal fees of $7,000.

*3i LP Institutional Investor Securities Purchase Agreement*

On January 23, 2025 (the "Closing Date") the Company entered into a Securities Purchase Agreement (the "Purchase Agreement") with an institutional investor (the "Investor"), pursuant to which the Investor will purchase, for an aggregate purchase price of $2,000,000, two senior convertible promissory notes (the "Notes") from the Company in the aggregate principal amount of $2,173,914 and two warrants (the "Warrants") to purchase up to an aggregate of 4,000,000 shares of the Company's common stock, par value $0.0001 per share, in each case subject to the terms and conditions set forth in the Purchase Agreement. Upon effectiveness of the registration rights agreement (the "Registration Rights Agreement") executed by the Company and the Investor on the Closing Date, the Company filed a registration statement with the Securities and Exchange Commission ("SEC") to register the shares of Common Stock issuable to the Investor upon any conversion of the Notes or exercise of the Warrants, within 15 days of the Closing Date. Pursuant to the Purchase Agreement, upon the registration statement being declared effective by the SEC on February 10, 2025, the Investor purchased a second Note in the principal amount of $1,086,957 and a second Warrant exercisable for up to an aggregate of 2,000,000 shares of Common Stock, for an aggregate purchase price of $1,000,000 on February 13, 2025.

The Notes mature on the anniversary of their date of issuance, unless prior thereto there is an event of default, bear interest at a rate of 7% per annum, have an 8% original issuance discount, are an unsecured obligation of the Company and rank equal in right of payment with the Company's existing indebtedness and senior to any future debt obligations of the Company through the repayment of the Notes. The outstanding principal amount of the Notes or any portion thereof is convertible into shares of Common Stock at a price of $0.25 per share (the "Conversion Price"); provided that no conversions can take place if the Investor then owns more than 4.99% (or up to 9.99% pursuant the terms of the Notes) of the number of the shares of Common Stock outstanding (the "Maximum Percentage"). Further, no conversion can take place, prior to approval by the Company's stockholders, if such conversion would violate any rule of the Nasdaq Stock Market. The Conversion Price is subject to adjustment in connection with certain transactions, including stock dividends, stock splits or combinations and the like. The Notes contain certain specified events of default, the occurrence of which would entitle the Investor to immediately demand repayment of all outstanding principal such as certain events of bankruptcy, insolvency and reorganization involving the Company.

The Warrants expire five years from their respective dates of issuance. The Warrants were exercisable, at the option of the holder, at any time, for up to an aggregate of 4,000,000 shares of Common Stock of the Company at an exercise price equal to $0.50, subject to adjustment for any stock splits, stock dividends, recapitalizations, and similar events.

 

On April 30, 2025, the Company made installment payments in cash totaling $232,608 on both 3i Notes or $116,304 for each 3i note, including principal, interest and make whole. The note was paid off in full as of September 30, 2025 and net liability as of September 30, 2025 and December 31, 2024 was approximately $0, respectively.

*Conversions*

 

During the nine months ended September 30, 2025, investors converted convertible promissory notes related to Austria Capital totaling $650,000 through the issuance of 2,600,000 shares of common stock that were issued and outstanding as of September 30, 2025. Additionally, during the nine months ended September 30, 2025, investors converted convertible promissory notes related to 3i totaling $881,085 through the issuance of 5,413,474 shares of common stock that were issued and outstanding as of September 30, 2025.

During 2024, investors converted convertible promissory notes totaling $4,010,022, including $3,950,000 of principal and $60,022 accrued interest, through the issuance of 4,050,617 shares of common stock that were issued and outstanding as of December 31, 2024.

**NOTE 8 — RELATED PARTIES**

On October 24, 2024, Dr. Joseph Sinkule and the Company entered into an Employment Agreement for a term of three years in connection with his appointment as the Company's Chief Executive Officer. Pursuant to the Employment Agreement, Dr. Sinkule will receive an annual base salary of $360,000 and an initial equity award of 1,000,000 options pursuant to the Company's 2023 Incentive Plan vesting immediately. The options are valid for a period of three (3) years and have an exercise price equal to the closing price of the Company's common stock on October 24, 2024. In addition, Dr. Sinkule will be eligible to participate in the Company's annual bonus program for executives.

On August 15, 2024, Mr. Jeffrey LeBlanc and the Company entered into an Employment Agreement for a term of three years in connection with his appointment as the Company's Chief Financial Officer, Pursuant to the Employment Agreement, Mr. LeBlanc will receive an annual base salary of $325,000 and an initial equity award of shares of the Company's common stock of 100,000 shares and an additional equity award of 400,000 shares of the Company's common stock, with 200,000 of such shares vesting on the first anniversary of the agreement and 200,000 of such shares vesting on the second anniversary of the agreement. In addition, Mr. LeBlanc will be eligible to participate in the Company's annual bonus program for executives.

On December 12, 2023, the Company issued a promissory note to a member of management. The promissory note accrued interest at a one-time interest fee of $2,460, which was paid off as of September 30, 2024. The unpaid principal balance was $0 and $31,000 at September 30, 2025 and December 31, 2024, respectively.

At September 30, 2025 and December 31, 2024, the aggregate related party payable was $0 and $31,000, respectively.

**NOTE 9 — STOCKHOLDER'S EQUITY**

On June 21, 2024, the Business Combination was completed. The transaction was accounted as a reverse recapitalization in accordance with GAAP. Under this method of accounting, Redwoods was treated as the "acquired" company for financial reporting purposes. Accordingly, for accounting purposes, the financial statements of the Combined Company represent a continuation of the financial statements of Klotho with the Transactions treated as the equivalent of Klotho issuing shares for the net assets of Redwoods, accompanied by a recapitalization. Accordingly, for accounting purposes, the Merger was treated as the equivalent of the Company issuing shares for the net assets of Redwoods, accompanied by a recapitalization. The net assets of Redwoods were stated at historical cost with no goodwill or other intangible assets recorded. See "NOTE 1 — Organization and Business Description" for detail.

 

*Equity Incentive Plan*

In connection with the Business Combination, the Company's Board adopted, and the Company's stockholders approved, the Equity Incentive Plan ("Equity Incentive Plan"). Although the Company does not have a formal policy with respect to the grant of equity incentive awards to the Company's executive officers, the Company believes that equity awards provide Company's executive officers with a strong link to the Company's long-term performance, create an ownership culture and help to align the interests of the Company's executives and the Company's stockholders. In addition, Company believes that equity awards with a time-based vesting feature promote executive retention because this feature provides incentives to Company's executive officers to remain in Klotho's employment during the applicable vesting period. Accordingly, Company's board of directors periodically reviews the equity incentive compensation of the Company's executive officers and from time to time may grant equity incentive awards to them.

*Warrants*

During the nine months ended September 30, 2025, the Company initiated a warrant exercise inducement program, reducing the exercise price from $3.49 to $1.35 for certain outstanding warrants. The Company accounted for the inducement as a modification of the original warrants in accordance with ASC 505-10 - Equity. The incremental fair value was recorded as a deemed dividend of $0.3 million in accumulated deficit on the condensed consolidated balance sheets. During the nine months ended September 30, 2025, holders of common stock warrants exercised a total of 11.0 million warrants for gross proceeds of $11.4 million.

*Austria Note Conversion*

During the three months ended June 30, 2025, $650,000 of principal related to the Austria Capital LLC Convertible Promissory Note was converted into 2,600,000 shares of common stock at a conversion price of $0.25. The remainder of the note in the amount of $550,000 was settled in cash. Therefore, the Company de-recognized the remaining unamortized original issue discount of $85,554 and deferred financing costs of $438,471, which were recognized in interest expense on the condensed consolidated statements of operations. During the three months ended September 30, 2025, the Company issued 2,000,000 additional shares in connection with settlement of the note, resulting in interest expense of $1,178,000.

*3i Note Conversion*

During the nine months ended September 30, 2025, $823,444 of principal and $57,641 of interest and make whole related to 3i convertible notes was converted into 5,413,474 shares of common stock at conversion prices ranging from $0.12 to $0.25.

*Investor Share Purchase*

On June 5, 2025, the Company entered into a securities purchase agreement with an accredited investor pursuant to Regulation D of the Securities Act of 1933, as amended. Under the terms of the agreement, the Company issued 6,250,000 shares of its common stock at a purchase price of $0.08 per share, for total gross proceeds of $500,000. The proceeds were allocated to common stock based upon their par value of the common stock and the remainder in recorded to additional paid in capital on the condensed consolidated balance sheets.

*Preferred B Shares*

 

On June 9, 2025, the Company conducted a private offering and issued 500 preferred B shares at $0.0001 par value per share for a total of $500,000. The 500 preferred shares are convertible into 6,250,000 common shares. During the three months ended September 30, 2025, all 500 preferred B shares were converted into 6,250,000 common shares.

*Meteora Agreement*

On June 13, 2024, RWOD and Klotho entered into a forward purchase agreement with (i) Meteora Capital Partners, LP ("MCP"), (ii) Meteora Select Trading Opportunities Master, LP ("MSTO"), and (iii) Meteora Strategic Capital, LLC ("MSC" and, collectively with MCP and MSTO, the "Seller") (the "Forward Purchase Agreement"). Redwoods is the holder of the asset and Sponsor and is also a counterparty to Klotho. Upon Closing of the merger on June 21, 2024 and on September 30, 2024, the value of the contract was $0 as the contract created no receivable or obligation for the Company. On September 19, 2024, the Company modified the settlement amount price of the contract to $2.00 and allowed the shares held with Meteora to be sold at Meteora's sole discretion, with the reset price subject to weekly changes. During the quarter ending March 31, 2025, Meteora sold and terminated on behalf of the Company 100,000 shares at a reset price of $0.4610, for total proceeds to Klotho in the amount of $46,100. On May 15, 2025, Meteora terminated an additional 550,214 shares at a reset price of $0.1717 for total proceeds of $94,472, thereby reducing the number of shares per the agreement to 10,000 shares remaining.

During the three months ended September 30, 2025, the Company entered into a second amendment (the "Second Amendment") to the Forward Purchase Agreement with MCP which primarily (i) increased the maximum number of shares to 6,755,000 and (ii) modified the reset price to $10.00 subject to a reset on a weekly basis. In connection with the modification, which relates to the reverse merger, the Company issued 6,745,000 common shares under the arrangement to MCP. The Company recognized the common shares at par value in the amount of $675 on the consolidated balance sheets with a corresponding recording of additional paid-in capital.

*At-the-Market Sales Agreement*

On July 3, 2025, the Company entered into a sales agreement with A.G.P./Alliance Global Partners ("A.G.P.") relating to the sale of newly issued shares of the Company's common stock. In accordance with the terms of the sales agreement, the Company may offer and sell shares of its common stock having an aggregate offering amount of up to $50,000,000 from time to time through A.G.P., acting as the Company's sales agent or principal. The Company intends to use the net proceeds from the offering for working capital and for general corporate purposes.

During the three months ended September 30, 2025, the Company sold 5,000 shares at a price of $1.06 per share for gross proceeds of $5,300.

**NOTE 10 — COMMITMENTS AND CONTINGENCIES**

From time to time, the Company is subject to various legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. Although the outcome of the various legal proceedings and claims cannot be predicted with certainty, management does not believe that any of these proceedings or other claims will have a material effect on the Company's business, financial condition, results of operations or cash flows.

*Termination of acquisition agreement of SB Security Holdings, LLC*

On March 26, 2025, the Company entered into a Share Exchange Agreement (the "SEA") to acquire SB Security Holdings, LLC, a Delaware limited liability company ("SBSH"), which is an internet connected video doorbell service company. Pursuant to the SEA, the Company agreed to purchase all of the issued and outstanding membership interests in SBSH (the "Acquisition") in exchange for a number of newly issued shares of the Company's common stock equal to ninety percent (90%) of the total number of issued and outstanding shares of the Company's common stock, on a fully-diluted basis, as of the closing of the Acquisition. The closing of the Acquisition is subject to customary closing conditions, including mutual agreement as to the legal transaction structure, approval by the Company's stockholders, and Nasdaq approval. On June 13, 2025, the Company terminated the SEA.

*NASDAQ Deficiencies*

On September 19, 2025, Klotho Neurosciences, Inc. (the "Company") received a delinquency notification letter (the "Notice") from the Nasdaq Stock Market LLC ("Nasdaq") due to the failure of the Company's common stock to maintain a minimum bid price of $1 per share for 30 consecutive business days as required by Nasdaq Listing Rule 5550(a)(2).

In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided 180 calendar days, or until March 18, 2026, to regain compliance. To regain compliance, prior to March 18, 2026, the closing bid price of the Company's common stock must be at least $1 for a minimum of ten consecutive business days.

**NOTE 11 — SEGMENT INFORMATION**

Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker ("CODM") in deciding how to allocate resources to an individual segment and in assessing performance. The Company operates as a single reporting segment, focused on developing essential medicines for the treatment of chronic diseases – cancer, cardiovascular, and neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and two proprietary, patented technologies involving the melanocortin receptor-binding molecules and a gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called "Klotho" inside the body to treat neurodegenerative diseases.

The Company's measure of segment profit or loss is net loss. The CODM is the chief executive officer ("CEO"). The CODM manages and allocates resources to the operations of the Company on a total company basis. Managing and allocating resources on a consolidated basis enables the CEO to assess the overall level of resources available and how to best deploy these resources across functions and research and development projects that are in line with the Company's long-term company-wide strategic goals. Consistent with this decision-making process, the CEO uses consolidated financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources, and setting incentive targets. Operating expenses are used to monitor budget versus actual results. The CODM also uses net loss in competitive analysis by benchmarking to the Company's peer group. The competitive analysis along with the monitoring of budgeted versus actual results are used in assessing performance of the segment.

The following table is representative of the significant expense categories regularly provided to the CODM when managing the Company's single reporting segment. A reconciliation to the consolidated net loss for the periods ended September 30, 2025 and 2024 is included at the bottom of the table below.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the Three Months Ended <br> September 30,** | **For the Three Months Ended <br> September 30,** | **For the Nine Months Ended <br> September 30,** | **For the Nine Months Ended <br> September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| **Significant segment expenses** |  |  |  |  |
| General and administrative<sup>(1)</sup> | $231404 | $52152 | $925563 | $63428 |
| Research and development | 271145 | - | 509845 | - |
| Professional fees - Licenses and Patents | - | - | - | 288416 |
| Professional fees - Other | 711169 | 903442 | 2372435 | 1346374 |
| Share-based compensation expense | 639586 | 1952852 | 1525281 | 1990366 |
| Interest expense | 1177999 | 44956 | 3491961 | 60020 |
| Other segment items | (56271) | 47046 | 369199 | 335830 |
| Total operating and segment expenses | $2975032 | $3000448 | $9194284 | $4084434 |
| **Reconciliation of net loss** |  |  |  |  |
| Change in fair value of warrant liabilities | (79447) | (41022) | 28514 | (1325) |
| Consolidated net loss | $2895585 | $2959426 | $9222798 | $4083109 |

---

1) Excluding share-based compensation expense

**NOTE 12 — SUBSEQUENT EVENTS**

The Company has evaluated subsequent events pursuant to the requirements of ASC Topic 855, from the balance sheet date through the date the financial statements were issued, and has determined that the following subsequent event exists:

Subsequent to September 30, 2025 the Company settled 2,201,930 common shares sold under its At-The-Market facility. Of these shares, 735,428 shares were initiated for sale on September 30, 2025, settled October 1, 2025, for net proceeds of approximately $339,000. The remaining 1,466,502 common shares were initiated for sale and settled subsequent to September 30, 2025, for net proceeds of approximately $737,000.

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

References in this report (this "Quarterly Report") to "we," "us" or the "Company" refer to Klotho Neurosciences, Inc. References to our "management" or our "management team" refer to our officers and directors. The following discussion and analysis of the Company's financial condition and results of operations should be read in conjunction with the unaudited condensed consolidated financial statements and the notes thereto contained elsewhere in this Quarterly Report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

**Special Note Regarding Forward-Looking Statements**

This Quarterly Report includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), that are not historical facts and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected. All statements, other than statements of historical fact included in this Quarterly Report, including, without limitation, statements in this "Management's Discussion and Analysis of Financial Condition and Results of Operations" regarding the search for an initial business combination, the Company's financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements. Words such as "expect," "believe," "anticipate," "intend," "estimate," "seek" and variations and similar words and expressions are intended to identify such forward-looking statements. Such forward-looking statements relate to future events or future performance, but reflect management's current beliefs, based on information currently available. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the Risk Factors section of the Company's final prospectus for its initial public offering filed with the U.S. Securities and Exchange Commission (the "SEC"). The Company's filings with the SEC can be accessed on the EDGAR section of the SEC's website at www.sec.gov. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

**Overview**

Klotho Neurosciences, Inc. ("The Company" or "Klotho") develops essential medicines for the treatment of chronic diseases – cancer, cardiovascular, and neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and two proprietary, patented technologies involving the melanocortin receptor-binding molecules and a gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called "Klotho" inside the body to treat neurodegenerative diseases.

Effective September 17, 2024, the Company changed its legal name from ANEW Medical, Inc. to Klotho Neurosciences, Inc. This name change was approved by the Company's Board of Directors to better reflect the strategic focus of its proprietary products. Throughout these financial statements, references to the 'Company' refer to Klotho Neurosciences, Inc., formerly known as ANEW or ANEW Public. Under certain circumstances, references to ANEW and ANEW Public have remained when useful in describing the sequence of events that occurred during the merger between Redwoods and ANEW.

As of May 30, 2023, Redwoods Acquisition Corp., a Delaware corporation and a special purpose acquisition company ("Redwoods"), Anew Medical Sub, Inc., a Wyoming corporation ("Merger Sub") and ANEW Medical, Inc., a Wyoming corporation ("ANEW") entered into a Business Combination Agreement, which was amended as of November 4, 2023 (the "Business Combination Agreement"). On June 21, 2024 (the "Closing Date"), Merger Sub merged with and into ANEW, with ANEW continuing as the surviving corporation and as a wholly owned subsidiary of Redwoods (the "Business Combination"). In connection with the Business Combination, on June 21, 2024, Redwoods filed a Second Amended Certificate of Incorporation with the Delaware Secretary of State, and adopted the amended and restated bylaws (the "Amended and Restated Bylaws"), which replaced Redwoods' Charter and Bylaws in effect as of such time. In connection with the closing of the Business Combination (the "Closing"), Redwoods changed its name to "ANEW Medical, Inc."

**Critical Accounting Policies and Estimates**

See Item 1, Note 2 – "Summary of Significant Accounting Policies."

**Results of Operations** 

For accounting purposes, the transactions contemplated by the Business Combination are treated as a reverse acquisition and, as such, the historical financial statements of the accounting acquirer Klotho will become the historical financial statements of Public ANEW. Under this method of accounting, Redwoods was treated as the acquired company for financial reporting purposes. Accordingly, for accounting purposes, the Merger was treated as the equivalent of the Company issuing shares for the net assets of Redwoods, accompanied by a recapitalization. The net assets of Redwoods were stated at historical cost with no goodwill or other intangible assets recorded.

We have not generated any operating revenues to date. To date, the Company's operations have consisted of acquiring our licensed platforms and patents, and planning for the Business Combination. We incur expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as our expenses associated with planning our research and clinical testing operations.

**Results of Operations for the Three Months Ended September 30, 2025 Compared to the Three Months Ended September 30, 2024**

***Revenues***

 ****

The Company had no revenue for the three months ended September 30, 2025 and 2024.

***Operating Expenses***

Our operating expenses for the three months ended September 30, 2025 were $1,853,304 compared to $2,870,932 for the three months ended September 30, 2024, a decrease of $1,017,628. The decrease was primarily due to decreases in share-based compensation and professional fees, partially offset by increases in research and development and general and administrative costs.

***Net Loss***

For the three months ended September 30, 2025, we incurred a net loss of $2,895,585 compared to a net loss of $2,959,426 for the three months ended September 30, 2024. The decrease in net loss was primarily due to decreased share-based compensation expense and professional fees, partially offset primarily by increases in interest expense, research and development efforts and general and administrative costs.

**Results of Operations for the Nine Months Ended September 30, 2025 Compared to the Nine Months Ended September 30, 2024**

***Revenues***

 ****

The Company had no revenue for the nine months ended September 30, 2025 and 2024.

***Operating Expenses***

Our operating expenses for the nine months ended September 30, 2025 were $5,333,124 compared to $3,688,584 for the nine months ended September 30, 2024, an increase of $1,644,540. The increase was primarily due to increases in professional fees, general and administrative costs and research and development efforts, partially offset by a decrease in share-based compensation.

***Net Loss***

For the nine months ended September 30, 2025, we incurred a net loss of $9,222,798 compared to a net loss of $4,083,109 for the nine-month period ended September 30, 2024. The increase in net loss was primarily due to increased interest expense, professional fees, general and administrative costs and research and development efforts, partially offset by a decrease in share-based compensation.

**Liquidity and Capital Resources**

---

| | | |
|:---|:---|:---|
|  | **Nine Months Ended<br> September 30,** | **Nine Months Ended<br> September 30,** |
|  | **2025** | **2024** |
| Net cash used in operating activities | $(4610390) | $(2002358) |
| Net cash used in investing activities |  | (123497) |
| Net cash provided by financing activities | 11894683 | 2173942 |
| Net increase (decrease) in cash and cash equivalents | $7284293 | $48087 |
| Cash, beginning of period | 63741 | 2808 |
| Cash, end of period | $7348034 | $50895 |

---

 ****

***Operating Activities***

Net cash used in operating activities for the nine months ended September 30, 2025 was $4,610,390, compared to $2,002,358, for the nine months ended September 30, 2024. The increase in cash used in operating activities is primarily attributable to increases in expenses related to continued operating costs. We expect net cash used in operating activities to increase in the coming periods, until our products are able to produce meaningful revenue.

***Investing Activities***

 ****

Net cash used in investing activities for the nine months ended September 30, 2025 was $0, compared to $123,497 for the nine months ended September 30, 2024, a decrease of $123,497. The decrease in cash used in investing activities is attributable to the Company not purchasing any new licenses eligible to be capitalized during the period.

***Financing Activities***

Net cash provided by financing activities for the nine months ended September 30, 2025 was $11,894,683, which consisted of investments, debt paydown, as well as proceeds from sales of common and preferred shares and warrants.

Net cash provided by financing activities for the nine months ended September 30, 2024 was $2,173,942, which consisted of proceeds from issuance of a convertible promissory note $1,000,000, proceeds from the sale of stock and warrants, net of $175,000, proceeds from shareholders of $120,000, proceeds from related party loans of $100,000 and merger proceeds net of transaction costs of $778,942.

**Liquidity, Capital Resources and Going Concern**

As of September 30, 2025, the Company had cash and cash equivalents of $7,348,034 and net working capital of $7,680,699.

The Company has incurred and expects to continue to incur significant professional costs to remain as a publicly traded company as well as incurred significant transaction costs related to the consummation of the Business Combination.

The accompanying condensed consolidated financial statements have been prepared as if the Company will continue as a going concern. The Company has incurred significant operating losses and negative cash flows from operations since inception. As of September 30, 2025, the Company had cash and cash equivalents of approximately $7.3 million and an accumulated deficit of approximately $19.8 million. The Company has incurred recurring losses, has experienced recurring negative operating cash flows, and requires significant cash resources to execute its business plans. The Company is dependent on obtaining additional working capital funding from the sale of equity and/or debt securities in order to continue to execute its development plans and continue operations. Without additional funding, there is substantial doubt about the Company's ability to continue as a going concern for twelve months from the date of these financial statements.

**Off-Balance Sheet Arrangements**

We have no obligations, assets or liabilities, which would be considered off-balance sheet arrangements as of September 30, 2025. We do not participate in transactions that create relationships with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets.

**Emerging Growth Company Status**

We are an "emerging growth company", as defined in the JOBS Act, and, for as long as we continue to be an emerging growth company, we may choose to take advantage of exemptions from various reporting requirements applicable to other public companies but not to emerging growth companies, including, but not limited to, not being required to have our independent registered public accounting firm audit our internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. As an emerging growth company, we can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We intend to avail ourselves of these options. Once adopted, we must continue to report on that basis until we no longer qualify as an emerging growth company.

We will cease to be an emerging growth company upon the earliest of: (i) the end of the fiscal year following the fifth anniversary of our initial public offering; (ii) the first fiscal year after our annual gross revenue are $1.07 billion or more; (iii) the date on which we have, during the previous three-year period, issued more than $1.0 billion in non-convertible debt securities; or (iv) the end of any fiscal year in which the market value of our common stock held by non-affiliates exceeded $700 million as of the end of the second quarter of that fiscal year. We cannot predict if investors will find our common stock less attractive if we choose to rely on these exemptions. If, as a result of our decision to reduce future disclosure, investors find our common stock less attractive, there may be a less active trading market for our common stock and the price of our common stock may be more volatile.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk**

As a smaller reporting company, we are not required to make disclosures under this Item.

**Item 4. Controls and Procedures**

 

**Evaluation of Disclosure Controls and Procedures**

 

Our management has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")), as of December 31, 2024. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of December 31, 2024, our disclosure controls and procedures were ineffective to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act (a) is recorded, processed, summarized and reported within the time periods specified by Securities and Exchange Commission ("SEC") rules and forms and (b) is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding any required disclosure. 

 

Management has identified control deficiencies regarding inadequate accounting resources, the lack of segregation of duties and the need for a stronger internal control environment. Management of the Company believes that these material weaknesses are due to the small size of the Company's accounting staff. The small size of the Company's accounting outsourced staff may prevent adequate controls in the future due to the cost/benefit of such remediation.

To mitigate the current limited resources and limited employees, we rely heavily on direct management oversight of transactions, along with the use of external legal and accounting professionals. As we grow, we expect to increase our number of employees, which will enable us to implement adequate segregation of duties within the internal control framework.

These control deficiencies could result in a misstatement of account balances that would result in a reasonable possibility that a material misstatement to our financial statements may not be prevented or detected on a timely basis. In light of this material weakness, we have made the following improvements:

● Conducted a risk assessment to identify gaps in internal controls over financial reporting

● Enhanced existing controls and implemented new controls as needed to address control gaps effective September 30, 2025

● Tested key controls to verify operating effectiveness as of September 30, 2025

● Documented narratives detailing enhanced processes and controls

Accordingly, management believes that our financial statements for the quarter ended September 30, 2025 are fairly stated, in all material respects, in accordance with GAAP.

*Changes in Int ernal Control Over Financial Reporting*

Except for the changes described above related to the implementation and enhancement of controls and documentation, there were no other changes in our internal controls over financial reporting that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

**PART II - OTHER INFORMATION**

**Item 1. Legal Proceedings**

None.

**Item 1A. Risk Factors**

As a smaller reporting company, we are not required to make disclosures under this Item.

**Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities**

None.

**Item 3. Defaults Upon Senior Securities**

None.

**Item 4. Mine Safety Disclosures**

Not applicable.

**Item 5. Other Information**

*Insider Trading Arrangements and Policies*

During the quarter ended September 30, 2025, none of the Company's directors or officers adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as those terms are defined in Regulation S-K, Item 408, that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

**Item 6. Exhibits**

The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 19.1\*\*\* | [Klotho Neurosciences, Inc. Insider Trading Policy (incorporated by reference to Exhibit 19.1 filed by Klotho Neurosciences, Inc.'s on Form 10-Q filed with the SEC on November 19, 2024).](https://www.sec.gov/Archives/edgar/data/1907223/000121390024100218/ea022156301ex19-1_klotho.htm) |
| 31.1\* | [Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](ea026445901ex31-1_klotho.htm) |
| 31.2\* | [Certification of Principal Accounting and Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](ea026445901ex31-2_klotho.htm) |
| 32.1\*\* | [Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ea026445901ex32-1_klotho.htm) |
| 32.2\*\* | [Certification of Principal Accounting and Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ea026445901ex32-2_klotho.htm) |
| 97.1\*\*\* | [Clawback policy (incorporated by reference to Exhibit 97.1 filed by Redwoods on Form 10-K filed by the Registrant on April 17, 2024).](https://www.sec.gov/Archives/edgar/data/1907223/000121390024033573/ea020298601ex97-1_redwoods.htm) |
| 101.INS\* | Inline XBRL Instance Document |
| 101.SCH\* | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL\* | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF\* | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB\* | Inline XBRL Taxonomy Extension Labels Linkbase Document |
| 101.PRE\* | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104\* | Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit) |

---

\* Filed herewith.

\*\* Furnished herewith. This certification is being furnished solely to accompany this report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filings of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

\*\*\* Filed previously.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **KLOTHO NEUROSCIENCES, INC.** | **KLOTHO NEUROSCIENCES, INC.** |
| Date: November 13, 2025 | By: | */s/ Joseph A. Sinkule* |
|  | Name: | Joseph A. Sinkule |
|  | Title: | Chief Executive Officer |
|  |  | (Principal Executive Officer) |
| Date: November 13, 2025 | By: | */s/ Jeffrey LeBlanc* |
|  | Name: | Jeffrey LeBlanc |
|  | Title: | Chief Financial Officer<br> (Principal Accounting Officer) |

---

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER**

**PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Joseph A. Sinkule, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this quarterly report on Form 10-Q for the quarterly period ended September 30, 2025 of Klotho Neurosciences, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) (Paragraph omitted pursuant to Exchange Act Rules 13a-14(a) and 15d-15(a));

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: November 13, 2025 | */s/* Joseph A. Sinkule |
|  | Joseph A. Sinkule |
|  | Chief Executive Officer |
|  | (Principal Executive Officer) |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION OF PRINCIPAL ACCOUNTING AND FINANCIAL OFFICER**

**PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Jeffrey LeBlanc, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this quarterly report on Form 10-Q for the quarterly period ended September 30, 2025 of Klotho Neurosciences, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) (Paragraph omitted pursuant to Exchange Act Rules 13a-14(a) and 15d-15(a));

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: November 13, 2025 | /s/ Jeffrey LeBlanc |
|  | Jeffrey LeBlanc |
|  | Chief Financial Officer |
|  | (Principal Accounting Officer) |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION**

**PURSUANT TO 18 U.S.C. SECTION 1350**

**AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Klotho Neurosciences, Inc. (the "Company") on Form 10-Q for the quarterly period ended September 30, 2025, as filed with the Securities and Exchange Commission (the "Report"), I, Joseph A. Sinkule, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| Date: November 13, 2025 | */s/* Joseph A. Sinkule |
|  | Joseph A. Sinkule |
|  | Chief Executive Officer |
|  | (Principal Executive Officer) |

---

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION**

**PURSUANT TO 18 U.S.C. SECTION 1350**

**AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Klotho Neurosciences, Inc. (the "Company") on Form 10-Q for the quarterly period ended September 30, 2025, as filed with the Securities and Exchange Commission (the "Report"), I, Jeffrey LeBlanc, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| Date: November 13, 2025 | */s/* Jeffrey LeBlanc |
|  | Jeffrey LeBlanc |
|  | Chief Financial Officer |
|  | (Principal Accounting Officer) |

---